Fonterra Admits Anchor Butter "Grass-Fed" Label Misled Consumers After Greenpeace Lawsuit 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
Deere & Company Agrees to $99 Million Settlement Over Right-to-Repair Dispute 
LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Private Credit Under Pressure: Is a Slow-Motion Crisis Unfolding? 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Ford Issues Major Recall on Over 422,000 Vehicles Due to Windshield Wiper Defect 
Trump Administration Plans 100% Tariffs on Pharmaceutical Imports 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Apple Turns 50: From Garage Startup to AI Crossroads 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
BRISBANE, Calif., July 27, 2017 -- CareDx, Inc. (Nasdaq:CDNA), a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value diagnostic solutions for transplant patients, today announced that it will release financial results for the second quarter 2017 after the market closes on Thursday, August 10, 2017. Peter Maag, Chief Executive Officer, and Michael Bell, Chief Financial Officer, will host a conference call to review the Company’s results beginning at 1:30pm PT/4:30pm ET.
Individuals interested in listening to the conference call may do so by dialing (855) 420-0616 for domestic callers or (678) 304-6848 for international callers. Please reference Conference ID: 56083631. To listen to a live webcast, please visit the investor relations section of CareDx's website at: www.CareDx.com.
A replay of the call will be available beginning August 10, 2017 at 4:30 pm PT/7:30 pm ET through 4:30 pm PT/7:30 pm ET on August 11, 2017. To access the replay, dial (855) 859-2056 or (404) 537-3406 and reference Conference ID: 56083631. The webcast will also be available on CareDx's website for one year following the completion of the call.
About CareDx
CareDx, Inc., headquartered in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of clinically differentiated, high-value solutions for transplant recipients. CareDx offers products across the transplant testing continuum, including AlloMap® and AlloSure™ for post-transplant surveillance and Olerup SSP®, Olerup QTYPE®, and Olerup SBT™ for pre-transplant HLA testing.
For more information, please visit: www.CareDx.com.
Investor Contact Caroline Corner, Managing Director Westwicke Partners, LLC T: +1 415-202-5678 E: [email protected]
